QQQ   294.43 (-0.06%)
AAPL   142.74 (-1.07%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.27 (+1.66%)
BABA   113.01 (+2.55%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.08 (+0.75%)
DIS   108.54 (+0.05%)
AMC   5.54 (+3.55%)
PFE   43.77 (-0.88%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   142.74 (-1.07%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.27 (+1.66%)
BABA   113.01 (+2.55%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.08 (+0.75%)
DIS   108.54 (+0.05%)
AMC   5.54 (+3.55%)
PFE   43.77 (-0.88%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   142.74 (-1.07%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.27 (+1.66%)
BABA   113.01 (+2.55%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.08 (+0.75%)
DIS   108.54 (+0.05%)
AMC   5.54 (+3.55%)
PFE   43.77 (-0.88%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
QQQ   294.43 (-0.06%)
AAPL   142.74 (-1.07%)
MSFT   247.22 (-0.24%)
META   147.61 (-0.91%)
GOOGL   98.39 (-0.46%)
AMZN   102.39 (-0.72%)
TSLA   173.80 (+0.33%)
NVDA   199.87 (+2.30%)
NIO   12.27 (+1.66%)
BABA   113.01 (+2.55%)
AMD   79.66 (+6.00%)
T   20.42 (+0.25%)
MU   61.08 (+1.29%)
F   13.65 (+1.04%)
CGC   3.04 (+0.33%)
GE   81.08 (+0.75%)
DIS   108.54 (+0.05%)
AMC   5.54 (+3.55%)
PFE   43.77 (-0.88%)
PYPL   81.13 (-0.44%)
NFLX   352.39 (-0.42%)
NYSE:BMY

Bristol-Myers Squibb - BMY Stock Forecast, Price & News

$72.80
+0.15 (+0.21%)
(As of 02/1/2023 09:46 AM ET)
Add
Compare
Today's Range
$72.34
$72.94
50-Day Range
$71.01
$81.13
52-Week Range
$62.90
$81.43
Volume
1.14 million shs
Average Volume
7.90 million shs
Market Capitalization
$154.78 billion
P/E Ratio
23.71
Dividend Yield
3.17%
Price Target
$80.60

Bristol-Myers Squibb MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
10.9% Upside
$80.60 Price Target
Short Interest
Healthy
0.99% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.30
Upright™ Environmental Score
News Sentiment
-0.23mentions of Bristol-Myers Squibb in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$4.93 M Sold Last Quarter
Proj. Earnings Growth
3.95%
From $7.60 to $7.90 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

108th out of 1,053 stocks

Pharmaceutical Preparations Industry

41st out of 519 stocks


BMY stock logo

About Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Stock News Headlines

Bristol-Myers Squibb (BMY) Scheduled to Post Earnings on Thursday
Top Lithium Stock To Watch
Today's stock market news features a lithium stock with blue sky potential.
The Power of Dual Immunotherapy
Huge Upside Potential With "Staggering" Solar Demand
Global solar demand is "staggering" right now, according to Bloomberg. Solar installations are set to grow 30% this year alone. And the boom is just beginning, with increasing adoption of solar by commercial, non-profit, and public entities. With only 1% of commercial electricity demand served by on-site solar globally, there is HUGE opportunity for growth.
The No. 1 Stock to Keep an Eye on in 2023
See More Headlines
Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.

BMY Company Calendar

Last Earnings
10/26/2021
Ex-Dividend for 2/1 Dividend
1/05/2023
Today
2/01/2023
Dividend Payable
2/01/2023
Next Earnings (Confirmed)
2/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
11012210
Employees
32,200
Year Founded
1887

Price Target and Rating

Average Stock Price Forecast
$80.60
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+10.7%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
14 Analysts

Profitability

Net Income
$6.99 billion
Pretax Margin
16.50%

Debt

Sales & Book Value

Annual Sales
$46.39 billion
Cash Flow
$12.53 per share
Book Value
$16.22 per share

Miscellaneous

Outstanding Shares
2,126,160,000
Free Float
2,124,246,000
Market Cap
$154.78 billion
Optionable
Optionable
Beta
0.44

Social Links


Key Executives

  • Giovanni CaforioGiovanni Caforio
    Chairman & Chief Executive Officer
  • David V. ElkinsDavid V. Elkins
    Chief Financial Officer & Executive Vice President
  • Rupert J. VesseyRupert J. Vessey
    Executive VP-Research & Early Development
  • Samit Hirawat
    Chief Medical Officer-Global Drug Development
  • Greg Meyers
    Chief Digital & Technology Officer













BMY Stock - Frequently Asked Questions

Should I buy or sell Bristol-Myers Squibb stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.
View BMY analyst ratings
or view top-rated stocks.

What is Bristol-Myers Squibb's stock price forecast for 2023?

14 Wall Street research analysts have issued twelve-month target prices for Bristol-Myers Squibb's shares. Their BMY share price forecasts range from $60.00 to $95.00. On average, they predict the company's share price to reach $80.60 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price.
View analysts price targets for BMY
or view top-rated stocks among Wall Street analysts.

How have BMY shares performed in 2023?

Bristol-Myers Squibb's stock was trading at $71.95 at the beginning of 2023. Since then, BMY stock has increased by 1.0% and is now trading at $72.65.
View the best growth stocks for 2023 here
.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 20,960,000 shares, an increase of 14.8% from the December 31st total of 18,250,000 shares. Based on an average daily trading volume, of 9,070,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 1.0% of the shares of the stock are short sold.
View Bristol-Myers Squibb's Short Interest
.

When is Bristol-Myers Squibb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our BMY earnings forecast
.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, February 2nd at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 647-362-9199 with passcode "3734085".

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb (NYSE:BMY) posted its quarterly earnings data on Tuesday, October, 26th. The biopharmaceutical company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.92 by $0.08. The biopharmaceutical company had revenue of $11.62 billion for the quarter, compared to analysts' expectations of $11.52 billion. Bristol-Myers Squibb had a net margin of 14.29% and a trailing twelve-month return on equity of 50.30%. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.63 EPS.
Read the conference call transcript
.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 8th. Investors of record on Friday, January 6th will be given a dividend of $0.57 per share on Wednesday, February 1st. This represents a $2.28 annualized dividend and a dividend yield of 3.14%. The ex-dividend date of this dividend is Thursday, January 5th. This is a boost from the stock's previous quarterly dividend of $0.54.
Read our dividend analysis for BMY
.

Is Bristol-Myers Squibb a good dividend stock?

Bristol-Myers Squibb (NYSE:BMY) pays an annual dividend of $2.28 per share and currently has a dividend yield of 3.17%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 74.27%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BMY will have a dividend payout ratio of 28.86% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BMY.

When did Bristol-Myers Squibb's stock split?

Bristol-Myers Squibb's stock split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Giovanni Caforio's approval rating as Bristol-Myers Squibb's CEO?

659 employees have rated Bristol-Myers Squibb Chief Executive Officer Giovanni Caforio on Glassdoor.com. Giovanni Caforio has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.33%), M&G Investment Management Ltd. (0.21%), New York State Common Retirement Fund (0.18%), DekaBank Deutsche Girozentrale (0.18%), New York State Teachers Retirement System (0.12%) and Fort Washington Investment Advisors Inc. OH (0.10%). Insiders that own company stock include Adam Dubow, Ann Powell, Autenried Paul Von, Christopher S Boerner, David V Elkins, Dinesh C Paliwal, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Rupert Vessey and Sandra Leung.
View institutional ownership trends
.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $72.65.

How much money does Bristol-Myers Squibb make?

Bristol-Myers Squibb (NYSE:BMY) has a market capitalization of $154.47 billion and generates $46.39 billion in revenue each year. The biopharmaceutical company earns $6.99 billion in net income (profit) each year or $3.07 on an earnings per share basis.

How many employees does Bristol-Myers Squibb have?

The company employs 32,200 workers across the globe.

Does Bristol-Myers Squibb have any subsidiaries?
The following companies are subsidiares of Bristol-Myers Squibb: 1096271 B.C. ULC, 345 Park LLC, A.G. Medical Services P.A., AHI Investment LLC, AbVitro LLC, Abraxis BioScience Australia Pty Ltd., Abraxis BioScience Inc., Abraxis BioScience International Holding Company Inc., Abraxis BioScience LLC, Abraxis BioScience Puerto Rico LLC, Acetylon Pharmaceuticals Inc., Adnexus, Adnexus a Bristol-Myers Squibb R&D Company, Allard Labs Acquisition G.P., Amira Pharmaceuticals, Amira Pharmaceuticals Inc., Amylin Pharmaceuticals, Apothecon LLC, B-MS Generx Unlimited Company, BMS Benelux Holdings B.V., BMS Bermuda Nominees L.L.C., BMS Data Acquisition Company LLC, BMS Forex Company, BMS Holdings Sarl, BMS Holdings Spain S.L., BMS International Insurance Designated Activity Company, BMS Investco SAS, BMS Korea Holdings L.L.C., BMS Latin American Nominees L.L.C., BMS Luxembourg Partners L.L.C., BMS Omega Bermuda Holdings Finance Ltd., BMS Pharmaceutical Korea Limited, BMS Pharmaceuticals Germany Holdings B.V., BMS Pharmaceuticals International Holdings Netherlands B.V., BMS Pharmaceuticals Korea Holdings B.V., BMS Pharmaceuticals Mexico Holdings B.V., BMS Pharmaceuticals Netherlands Holdings B.V., BMS Real Estate LLC, BMS Spain Investments LLC, BMS Strategic Portfolio Investments Holdings Inc., Blisa Acquisition G.P., Bristol (Iran) S.A., Bristol Iran Private Company Limited, Bristol Laboratories Inc., Bristol Laboratories International S.A., Bristol Laboratories Medical Information Systems Inc., Bristol-Myers (Andes) L.L.C., Bristol-Myers (Private) Limited, Bristol-Myers Middle East S.A.L., Bristol-Myers Overseas Corporation, Bristol-Myers Squibb (China) Investment Co. Ltd., Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., Bristol-Myers Squibb (Israel) Ltd., Bristol-Myers Squibb (NZ) Limited, Bristol-Myers Squibb (Proprietary) Limited, Bristol-Myers Squibb (Shanghai) Trading Co. Ltd., Bristol-Myers Squibb (Singapore) Pte. Limited, Bristol-Myers Squibb (Taiwan) Ltd., Bristol-Myers Squibb (West Indies) Ltd., Bristol-Myers Squibb A.E., Bristol-Myers Squibb Aktiebolag, Bristol-Myers Squibb Argentina S. R. L., Bristol-Myers Squibb Australia Pty. Ltd., Bristol-Myers Squibb Axia Limited, Bristol-Myers Squibb B.V., Bristol-Myers Squibb Belgium S.A., Bristol-Myers Squibb Business Services Limited, Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Canada International Limited, Bristol-Myers Squibb Delta Company Limited, Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb AB, Bristol-Myers Squibb EMEA Sarl, Bristol-Myers Squibb Egypt LLC, Bristol-Myers Squibb Epsilon Holdings Unlimited Company, Bristol-Myers Squibb Farmaceutica Ltda., Bristol-Myers Squibb Farmaceutica Portuguesa S.A., Bristol-Myers Squibb GesmbH, Bristol-Myers Squibb GmbH & Co. KGaA, Bristol-Myers Squibb Holding Germany GmbH & Co. KG, Bristol-Myers Squibb Holdings 2002 Limited, Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH, Bristol-Myers Squibb Holdings Ireland Unlimited Company, Bristol-Myers Squibb Holdings Limited, Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company, Bristol-Myers Squibb Ilaclari Inc., Bristol-Myers Squibb India Pvt. Limited, Bristol-Myers Squibb International Company Unlimited Company, Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Investco L.L.C., Bristol-Myers Squibb K.K., Bristol-Myers Squibb Kft., Bristol-Myers Squibb Luxembourg International S.C.A., Bristol-Myers Squibb Luxembourg S.a.r.l., Bristol-Myers Squibb MEA GmbH, Bristol-Myers Squibb Manufacturing Company, Bristol-Myers Squibb Marketing Services S.R.L., Bristol-Myers Squibb Middle East & Africa FZ-LLC, Bristol-Myers Squibb Norway Ltd., Bristol-Myers Squibb Nutricionales de Mexico S. de R.L. de C.V., Bristol-Myers Squibb Peru S.A., Bristol-Myers Squibb Pharma (HK) Ltd, Bristol-Myers Squibb Pharma (Thailand) Limited, Bristol-Myers Squibb Pharma Company, Bristol-Myers Squibb Pharma EEIG, Bristol-Myers Squibb Pharma Holding Company LLC, Bristol-Myers Squibb Pharma Ventures Corporation, Bristol-Myers Squibb Pharmaceuticals Limited, Bristol-Myers Squibb Pharmaceuticals Unlimited Company, Bristol-Myers Squibb Polska Sp. z o.o., Bristol-Myers Squibb Products SA, Bristol-Myers Squibb Puerto Rico Inc., Bristol-Myers Squibb Puerto Rico/Sanofi Pharmaceutical Partnership Puerto Rico, Bristol-Myers Squibb Romania S.R.L., Bristol-Myers Squibb S.A.U., Bristol-Myers Squibb S.r.l., Bristol-Myers Squibb SA, Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, Bristol-Myers Squibb Sarl, Bristol-Myers Squibb Service Ltd., Bristol-Myers Squibb Services Sp. z o.o., Bristol-Myers Squibb Spol. s r.o., Bristol-Myers Squibb Theta Finance Ltd., Bristol-Myers Squibb Trustees Limited, Bristol-Myers Squibb Verwaltungs GmbH, Bristol-Myers Squibb de Colombia S.A., Bristol-Myers Squibb de Costa Rica Sociedad Anonima, Bristol-Myers Squibb de Guatemala S.A., Bristol-Myers Squibb de Mexico S. de R.L. de C.V., Bristol-Myers Squibb/Astrazeneca EEIG, Bristol-Myers Squibb/Pfizer EEIG, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, Bristol-Myers de Venezuela S.C.A., CHT I LLC, CHT II LLC, CHT III LLC, CHT IV LLC, CR Finance Company LLC, Cardioxyl Pharmaceuticals, Cardioxyl Pharmaceuticals Inc., Celem LLC, Celem Ltd., Celgene, Celgene A.B., Celgene AS, Celgene Ab (Finland), Celgene Alpine Investment Co. II LLC, Celgene Alpine Investment Co. III LLC, Celgene Alpine Investment Co. LLC, Celgene ApS, Celgene B.V., Celgene BVBA, Celgene Brasil Produtos Farmacêuticos Ltda., Celgene CAR LLC, Celgene CAR Ltd., Celgene Chemicals Sarl, Celgene China Holdings LLC, Celgene Co., Celgene Corporation, Celgene Distribution B.V., Celgene EngMab GmbH, Celgene Europe B.V., Celgene Europe Limited, Celgene European Investment Company LLC, Celgene Financing Company LLC, Celgene Global Holdings Sarl, Celgene GmbH [Austria], Celgene GmbH [Germany], Celgene GmbH [Switzerland], Celgene Holdings East Corporation, Celgene Holdings II Sarl, Celgene Holdings III Sarl, Celgene Ilaç Pazarlama ve Ticaret Limited Şirketi, Celgene Inc., Celgene International Holdings Corporation, Celgene International II Sàrl, Celgene International III Sàrl, Celgene International Inc., Celgene International Sàrl, Celgene K.K., Celgene Kft., Celgene Limited [Hong Kong], Celgene Limited [Ireland], Celgene Limited [New Zealand], Celgene Limited [Taiwan], Celgene Limited [UK], Celgene Logistics Sàrl, Celgene Ltd, Celgene Luxembourg Sarl, Celgene Management Sàrl, Celgene NJ Investment Co, Celgene Netherlands B.V., Celgene Netherlands Investment B.V., Celgene Pharmaceutical (Shanghai) Co. Ltd., Celgene Pte. Ltd., Celgene Pty Ltd, Celgene Puerto Rico Distribution LLC, Celgene Quanticel Research Inc, Celgene R&D Sàrl, Celgene RIVOT LLC, Celgene RIVOT Ltd., Celgene RIVOT SRL, Celgene Receptos Limited, Celgene Receptos Sàrl, Celgene Research Incubator At Summit West LLC, Celgene Research S.L.U., Celgene Research and Development Company LLC, Celgene Research and Development I ULC, Celgene Research and Development II LLC, Celgene Research and Investment Company II LLC, Celgene S. de R.L. de C.V., Celgene S.L.U., Celgene S.R.L., Celgene SAS, Celgene Sarl AU, Celgene Sdn Bhd, Celgene Services Sàrl, Celgene Sociedade Unipessoal Lda, Celgene Sp. Z.o.o., Celgene Sro [Czech Republic], Celgene Summit Investment Co, Celgene Switzerland Holding Sarl, Celgene Switzerland II LLC, Celgene Switzerland Investment Sarl, Celgene Switzerland LLC, Celgene Switzerland Sarl, Celgene Tri A Holdings Ltd., Celgene Tri Sarl, Celgene UK Distribution Limited, Celgene UK Holdings Limited, Celgene UK Manufacturing II Limited, Celgene UK Manufacturing III Limited, Celgene UK Manufacturing Limited, Celgene d.o.o., Celgene sro [Slovakia], Celmed LLC, Celmed Ltd., ConvaTec Divestiture, Cormorant Pharmaceuticals, Cormorant Pharmaceuticals AB, Crosp Ltd., Delinia Inc., Deuteria Pharmaceuticals Inc., DuPont Pharmaceuticals, E. R. Squibb & Sons Inter-American Corporation, E. R. Squibb & Sons L.L.C., E. R. Squibb & Sons Limited, EWI Corporation, EngMab Sarl, F-star Alpha, FermaVir Pharmaceuticals L.L.C., FermaVir Research L.L.C., Flexus Biosciences, Flexus Biosciences Inc., Forbius, Galecto Biotech, GenPharm International L.L.C., Gloucester Pharmaceuticals LLC, Grove Insurance Company Ltd., Heyden Farmaceutica Portuguesa Limitada, IFM Therapeutics, Impact Biomedicines Inc., Inhibitex, Inhibitex L.L.C., Innate Tumor Immunity Inc., JuMP Holdings LLC, Juno Therapeutics GmbH, Juno Therapeutics Inc., Kosan Biosciences, Kosan Biosciences Incorporated, Linson Investments Limited, Mead Johnson (Manufacturing) Jamaica Limited, Mead Johnson Jamaica Ltd., Medarex, Morris Avenue Investment II LLC, Morris Avenue Investment LLC, MyoKardia, O.o.o. Bristol-Myers Squibb, Oy Bristol-Myers Squibb (Finland) AB, Padlock Therapeutics, Padlock Therapeutics Inc., Pharmion LLC, Princeton Pharmaceutical Products Inc., Receptos LLC, Receptos Services LLC, RedoxTherapies Inc., Route 22 Real Estate Holding Corporation, SPV A Holdings ULC, Seamair Insurance DAC, Signal Pharmaceuticals LLC, Sino-American Shanghai Squibb Pharmaceuticals Limited, Societe Francaise de Complements Alimentaires(S.O.F.C.A.), Squibb Middle East S.A., Summit West Celgene LLC, Swords Laboratories, VentiRx Pharmaceuticals Inc., Westwood-Intrafin SA, Westwood-Squibb Pharmaceuticals Inc., X-Body Inc., ZymoGenetics, ZymoGenetics Inc., ZymoGenetics LLC, ZymoGenetics Paymaster LLC, iPierian, and iPierian Inc..
Read More
How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The official website for the company is www.bms.com. The biopharmaceutical company can be reached via phone at (212) 546-4000, via email at john.elicker@bms.com, or via fax at 212-546-4020.

This page (NYSE:BMY) was last updated on 2/1/2023 by MarketBeat.com Staff